MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice

International Journal of Nanomedicine

Volumn 7, Issue , 2012, Pages 5957-5967

  Pan, Yang ^a,b   Jia, Tingting ^a,b   Zhang, Yuan ^a,b   Zhang, Kuo ^a   Zhang, Rui ^a   Li, Jinming ^a   Wang, Lunan ^a  

^a BEIJING HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Anti dsDNA antibody; Autoantibody to nuclear antigen; BXSB mice; Gene therapy; Systemic lupus erythematosus; Toll like receptor

Indexed keywords

ALPHA INTERFERON; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 6; MICRORNA 146A; TOLL LIKE RECEPTOR; MICRORNA; MIRN146 MICRORNA, MOUSE; NANOCAPSULE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE EXPRESSION; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MOUSE; NONHUMAN; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VIRAL GENE DELIVERY SYSTEM; VIRUS LIKE AGENT; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CHEMISTRY; COLIPHAGE; GENETIC TRANSFECTION; IMMUNOLOGY; METHODOLOGY; TREATMENT OUTCOME; VIRION;

ESCHERICHIA COLI; MUS;

ANIMALS; AUTOANTIBODIES; LEVIVIRUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; MICE, INBRED C57BL; MICRORNAS; NANOCAPSULES; TRANSFECTION; TREATMENT OUTCOME; VIRION;

EID: 84875822153     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S37990     Document Type: Article

References (42)

1. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explo-sion in systemic lupus erythematosus: more than 100 different anti-bodies found in SLE patients. Semin Arthritis Rheum. 2004;34(2): 501-537.
2. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929-939.
3. Yildirim-Toruner C, Diamond B. Current and novel therapeutics in the treatment of systemic lupus erythematosus. J Allergy Clin Immunol. 2011;127(2):303-314.
4. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 2005;122(4):553-563.
5. Dai R, Ahmed SA. MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases. Transl Res. 2011;157(4):163-179.
6. Ceribelli A, Yao B, Dominguez-Gutierrez PR, Nahid MA, Satoh M, Chan EK. MicroRNAs in systemic rheumatic diseases. Arthritis Res Ther. 2011;13(4):229.
7. Garchow BG, Encinas OB, Leung YT, et al. Silencing of microR6-21 in vivo ameliorates autoimmune splenomegaly in lupus mice. EMBO Mol Med. 2011;3(10):605-615.
8. Li L, Chen XP, Li YJ. MicroRNA-146a and human disease. Scand J Immunol. 2010;71(4):227-231.
9. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnor-mal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60(4): 1065-1075.
10. Boldin MP, Taganov KD, Rao DS, et al. miR-146a is a significant brake on autoimmunity, myeloproliferation, and cancer in mice. J Exp Med. 2011;208(6):1189-1201.
11. Davidson BL Jr, McCray PB. Current prospects for RNA interference-based therapies. Nat Rev Genet. 2011;12(5):329-340.
12. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492-503.
13. Wang J. Efficient gene knockdowns in mouse embryonic stem cells using microRNA-based shRNAs. Methods Mol Biol. 2010;650: 241-256.
14. Carrico ZM, Romanini DW, Mehl RA, Francis M. Oxidative coupling of peptides to a virus capsid containing unnatural amino acids. Chem Commun (Camb). 2008;14(10):1205-1207.
15. Kovacs EW, Hooker JM, Romanini DW, Holder PG, Berry KE, Francis MB. Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. Bioconjugate Chem. 2007;18(4):1140-1147.
16. Wu M, Sherwin T, Brown WL, Stockley PG. Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine. 2005;1(1):67-76.
17. Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus-like particles. FEBS J. 2012;279(7):1198-1208.
18. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402-408.
19. Wei B, Wei Y, Zhang K, et al. Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. Biomed Pharmacother. 2009; 64(3):313-318.
20. Izui S, Ibnou-Zekri N, Fossati-Jimack L, Iwamoto M. Lessons from BXSB and related mouse models. Int Rev Immunol. 2000;19(4-5):447-472.
21. Xu J, Zutter MM, Santoro SA, Clark RA. A three-dimensional colla-gen lattice activates NF-kappaB in human fibroblasts: role in integrin alpha2 gene expression and tissue remodeling. J Cell Biol. 1998;140(3): 709-719.
22. Nahid MA, Pauley KM, Satoh M, Chan EK. MiR-146a is criti-cal for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY. J Biol Chem. 2009;284(50):34590-34599.
23. Dai Y, Sui W, Lan H, Yan Q, Huang H, Huang Y. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009;29(7):749-754.
24. Te JL, Dozmorov IM, Guthridge JM, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS One. 2010;5(5):10344.
25. Dai R, Zhang Y, Khan D, et al. Identification of a common lupus disease-associated microRNA expression pattern in three different murine models of lupus. PLoS One. 2010;5(12):14302.
26. Sethupathy P, Collins FS. MicroRNA target site polymorphisms and human disease. Trends Genet. 2008;24(10):489-497.
27. Huppi K, Volfovsky N, Mackiewicz M, et al. MicroRNAs and genomic instability. Semin Cancer Biol. 2007;17(1):65-73.
28. Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455(7209):58-63.
29. Perry D, Sang A, Yin Y, Zheng YY, Morel L. Murine models of systemic lupus erythematosus. J Biomed Biotechnol. 2011;2011:271694.
30. Kono DH, Haraldsson MK, Lawson BR, et al. Endosomal TLR signaling is required for anti-nucleic acid and rheumatoid factor autoantibodies in lupus. Proc Natl Acad Sci U S A. 2009;106(29):12061-12066.
31. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature. 2002;416(6881): 603-607.
32. Marshak-Rothstein A. Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol. 2006;6(11):823-835.
33. Nickerson KM, Christensen SR, Shupe J, et al. TLR9 regulates TLR7-and MyD88-dependent autoantibody production and disease in a murine model of lupus. J Immunol. 2010;184(4):1840-1848.
34. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene. 2008; 27(42):5643-5647.
35. Pauley KM, Satoh M, Chan AL, Bubb MR, Reeves WH, Chan EK. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis Res Ther. 2008; 10(4):101.
36. Banchereau J, Pascual V. Type I interferon in systemic lupus erythemato-sus and other autoimmune diseases. Immunity. 2006;25(3):383-392.
37. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000;18(5): 565-570.
38. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 2004;13(5):339-343.
39. Yokoyama H, Kreft B, Kelley VR. Biphasic increase in circulating and renal TNF-alpha in MRL-lpr mice with differing regulatory mechanisms. Kidney Int. 1995;47(1):122-130.
40. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol. 1989;143(11): 3470-3475.
41. Rao DD, Senzer N, Cleary MA, Nemunaitis J. Comparative assess-ment of siRNA and shRNA off target effects: what is slowing clinical development. Cancer Gene Ther. 2009;16(11):807-809.
42. Singh S, Narang AS, Mahato RI. Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm Res. 2011;28(12):2996-3015.